Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries

1. WHO 2008 Guidelines for the evaluation of dengue vaccines in endemic areas. WHO/IVB/08.12. Available: http://www.who.int/immunization/documents/WHO_IVB_08.12/en/index.html. Accessed 18 January 2011

2. EdelmanR

HombachJ

2008 Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine 26 4113 4119

3. BeattyME

LetsonGW

MargolisHS

2008 Estimating the global burden of dengue. Second International Conference of Dengue and Dengue Haemorrhagic Fever; 15–17 October 2008; Phuket, Thailand

4. HerrlingP

2006 Experiments in social responsibility. Nature 439 267 268

5. Teixeira MdaG

Costa MdaC

BarretoML

MotaE

2005 Dengue and dengue hemorrhagic fever epidemics in Brazil: what research is needed based on trends, surveillance, and control experiences? Cad. Saude Publica de Janeiro, 2005. 21 1307 1315

6. HalsteadSB

2007 Dengue. Lancet 370 1644 1652

7. DouglasD

WichmannO

DeRoeckD

2009 The perceived need for dengue vaccine in dengue endemic countries. 3rd Vaccine Global Congress; 4–6 October 2009; Singapore

8. SabchareonA

ChanthavanichP

YoksanS

ForratR

2004 Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 99 109

9. SabchareonA

LangJ

ChanthavanichP

YoksanS

ForratR

2002 Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 264 272

10. SiqueiraJBJr

MartelliCM

CoelhoGE

SimplicioAC

HatchDL

2005 Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg Infect Dis 11 48 53

11. VanwambekeSO

van BenthemBH

KhantikulN

Burghoorn-MaasC

PanartK

2006 Multi-level analyses of spatial and temporal determinants for dengue infection. Int J Health Geogr 18 5

12. WichmannO

HongsiriwonS

BowonwatanuwongC

ChotivanichK

SukthanaY

2004 Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 9 1022 1029

13. BatsonA

GlassS

SeiguerE

2003 Economics of vaccines: from vaccine candidate to commercialized product.

BloomBR

LambertPH

The vaccine book London Academic Press 345 370

14. WhiteheadSS

BlaneyJE

DurbinAP

MurphyBR

2007 Prospects for a dengue virus vaccine. Nat Rev Microbiol 5 518 528

15. StandishK

KuanG

AvilésW

BalmasedaA

HarrisE

2010 High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. Am J Trop Med Hyg 4 e633

16. VongS

KhieuV

GlassO

LyS

DuonggV

2010 Dengue incidence in urban and rural Cambodia: results from population-based active Fever surveillance, 2006–2008 PLoS Negl Trop Dis 4 e903 doi:10.1371/journal.pntd.0000903

17. LetsonGW

2009 Dengue surveillance in preparation for field vaccine trials. J Clin Virol 46 S10 S12

18. BrennanMJ

FruthU

MilstienJ

TiernanR

de Andrade NishiokaS

2007 Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4 e252 doi:10.1371/journal.pmed.0040252

19. HombachJ

2007 Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica 21 254 260

20. HombachJ

BarrettAD

CardosaMJ

DeubelV

GuzmanM

2005 Review on flavivirus vaccine development: proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, Thailand. Vaccine 23 2689 2695

21. WHO 2007 Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07.07. Available: http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.07_eng.pdf. Accessed 18 January 2011